Ken Griffin Cyma Bay Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $2.74 Million - $5.31 Million	216,927 Added 191.45%	330,234 $7.8 Million
Q3 2023 Nov 14, 2023	SELL	$10.86 - $17.62 $3.65 Million - $5.92 Million	-336,155 Reduced 74.79%	113,307 $1.69 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $923,112 - $1.35 Million	123,576 Added 37.92%	449,462 $4.92 Million
Q1 2023 May 15, 2023	SELL	$5.88 - $9.59 $6.09 Million - $9.92 Million	-1,034,929 Reduced 76.05%	325,886 $2.84 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $29,488 - $57,420	9,158 Added 0.68%	1,360,815 $8.53 Million

Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $115,730 - $177,565	41,780 Added 3.19%	1,351,657 $4.73 Million
Q2 2022 Aug 15, 2022	BUY	$1.72 - $3.39 $589,960 - $1.16 Million	343,000 Added 35.48%	1,309,877 $3.86 Million
Q1 2022 May 16, 2022	BUY	$2.77 - $3.64 $776,827 - $1.02 Million	280,443 Added 40.86%	966,877 $3.01 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $1.86 Million - $2.65 Million	575,805 Added 520.48%	686,434 $2.32 Million
Q3 2021 Nov 15, 2021	SELL	$3.47 - $4.42 $838,587 - $1.07 Million	-241,668 Reduced 68.6%	110,629 $404,000
Q2 2021 Aug 16, 2021	SELL	$3.94 - $4.92 $4.84 Million - $6.05 Million	-1,228,678 Reduced 77.72%	352,297 $1.54 Million
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $3.99 Million - $6.17 Million	-942,450 Reduced 37.35%	1,580,975 $7.18 Million
Q4 2020 Feb 16, 2021	BUY	$5.73 - $9.03 $1.73 Million - $2.73 Million	301,870 Added 13.59%	2,523,425 $14.5 Million
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $1.59 Million - $3.46 Million	-478,543 Reduced 17.72%	2,221,555 $16.1 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $50,569 - $152,426	35,865 Added 1.35%	2,700,098 $9.42 Million
Q1 2020 May 15, 2020	SELL	$1.25 - $2.02 $240,068 - $387,951	-192,055 Reduced 6.72%	2,664,233 $3.94 Million
Q4 2019 Feb 14, 2020	BUY	$1.33 - $5.93 $750,050 - $3.34 Million	563,948 Added 24.6%	2,856,288 $5.6 Million
Q3 2019 Nov 14, 2019	SELL	$5.12 - $7.21 $142,305 - $200,394	-27,794 Reduced 1.2%	2,292,340 $11.7 Million
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $2.94 Million - $6.63 Million	-485,338 Reduced 17.3%	2,320,134 $16.6 Million
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $11.3 Million - $18.5 Million	1,379,650 Added 96.76%	2,805,472 $0
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $3.06 Million - $5.5 Million	468,574 Added 48.95%	1,425,822 $11.2 Million
Q3 2018 Nov 13, 2018	SELL	$10.88 - $14.52 $10.4 Million - $13.9 Million	-957,559 Reduced 50.01%	957,248 $0
Q2 2018 Aug 10, 2018	BUY	$10.66 - $14.38 $9.02 Million - $12.2 Million	846,407 Added 79.22%	1,914,807 $0
Q1 2018 May 11, 2018	BUY	$9.0 - $15.16 $3.37 Million - $5.67 Million	374,148 Added 53.89%	1,068,400 $13.9 Million
Q4 2017 Feb 09, 2018	BUY	$7.67 - $9.31 $415,905 - $504,834	54,225 Added 8.47%	694,252 $6.39 Million
Q3 2017 Nov 09, 2017	BUY	$5.95 - $8.26 $3.81 Million - $5.29 Million	640,027	640,027 $5.16 Million

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.88M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account